Parkinson's Disease

PD-GENEration: Assessing remote vs. in-person genetic testing and counseling in PD 3:06
PD-GENEration: Assessing remote vs. in-person genetic testing and counseling in PD
Jennifer Verbrugge • 14 Apr 2021
Hot topics at AAN 2021: COVID-19 and racial disparities in neurologic care 1:45
Hot topics at AAN 2021: COVID-19 and racial disparities in neurologic care
Chantale Branson • 7 Apr 2021
The complexities of Parkinson’s disease subtyping 3:04
The complexities of Parkinson’s disease subtyping
Alberto Espay • 12 Apr 2021
Improving levodopa delivery in PD 4:28
Improving levodopa delivery in PD
Daniele Urso • 19 Feb 2021
Dopamine agonist phobia in PD 4:51
Dopamine agonist phobia in PD
Lucia Batzu • 19 Mar 2021
The association between neurofilament light chain and non-motor PD symptoms 4:51
The association between neurofilament light chain and non-motor PD symptoms
Daniele Urso • 19 Mar 2021
Basal forebrain volume and LRRK2-associated PD 6:13
Basal forebrain volume and LRRK2-associated PD
Lucia Batzu • 19 Mar 2021
Moving from symptomatic therapy towards disease modification in PD 6:11
Moving from symptomatic therapy towards disease modification in PD
Anette Schrag • 15 Mar 2021
PASADENA trial: prasinezumab in early Parkinson’s disease 1:24
PASADENA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Glycation drives neurodegeneration in synucleinopathies 3:34
Glycation drives neurodegeneration in synucleinopathies
Tiago Outeiro • 16 Mar 2021
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease 1:29
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Learnings from the PASADENA trial in Parkinson’s disease 1:49
Learnings from the PASADENA trial in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
RNA-based processes linked to synapse degeneration in models of Parkinson’s disease 2:23
RNA-based processes linked to synapse degeneration in models of Parkinson’s disease
Tiago Outeiro • 16 Mar 2021
Doxycycline inhibits alpha-synuclein aggregation in PD models 2:43
Doxycycline inhibits alpha-synuclein aggregation in PD models
Tiago Outeiro • 16 Mar 2021
Age at onset and Parkinson’s disease progression 1:10
Age at onset and Parkinson’s disease progression
Gennaro Pagano • 10 Mar 2021
RAB39B involved in the pathogenesis of dementia with Lewy bodies 2:08
RAB39B involved in the pathogenesis of dementia with Lewy bodies
Tiago Outeiro • 16 Mar 2021
The content of VJNeurology is intended for healthcare professionals